resTORbio to Present at the Jefferies 2018 Global Healthcare Conference

BOSTON, June 01, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. TORC, a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that company management will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on Friday, June 8, 2018 at 2:00 p.m. ET in New York, NY.

A live audio webcast of the presentation can be accessed on the Investors section of resTORbio's website at http://ir.restorbio.com/investors. An archived replay will be available for at least 30 days following the presentation.

About resTORbio

resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio's lead program is targeting the selective inhibition of TORC1 - an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac and neurologic systems. RTB101, resTORbio's lead drug candidate, is a selective, orally administered, TORC1 inhibitor currently being investigated in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. The Company expects to develop RTB101 for additional aging-related indications such as heart failure or neurodegenerative diseases.

Contacts:

Michael Schaffzin

Stern Investor Relations, Inc.

212-362-1200

michael@sternir.com

Michael Lampe

Scient PR

484-575-5040

michael@scientpr.com

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!